such as protection from oxidative stress, are putative candidates Postgraduate Medicine, Keele University North Staffordshire Hospital, for susceptibility to multiple tumours. However, while data Stoke-on-Trent, Staffordshire, UK from case-control studies support this view, it is clear that the 5 To whom correspondence should be addressed concept of susceptibility to multiple BCC is complex, as Basal cell carcinoma (BCC) is the commonest cancer in genetic factors appear to influence both tumour numbers and Caucasians. Its incidence is rising and many patients their rate of appearance (7-10). A further important aspect of develop multiple primary tumours at separate sites. Factors susceptibility is the identification of genetic factors that infludetermining time between first primary tumour presentaence tumour site. Thus, compared with cutaneous squamous tion and the next new primary lesion are unclear. We cell cancer, BCC are more common on generally less exposed used Cox's proportional hazards model to study, in 856 sites especially the trunk (4,5) with lesions infrequently found Caucasians, the influence of tumour site, individual characon the forearms or backs of the hands. Also, while the incidence teristics and polymorphism in glutathione S-transferase of BCC is increasing, it is the proportion of tumours on the (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, trunk that demonstrates the greatest increase. The factors that CYP1A1) loci on time to next primary tumour presentation.
determine susceptibility to tumours on the trunk rather than More than one tumour at first presentation (P Ͻ0.0001, the more sun-exposed head and neck are unclear, though it hazard ratio 2.72) and GSTT1 null (P ϭ 0.028, hazard might be expected that truncal tumours are associated with ratio 1.74) were associated with decreased time to next different susceptibility genes. primary tumour presentation. Significant two-factor interVarious individual characteristics are associated with risk actions, corrected for number of tumours at presentation, of multiple BCC including skin type and male gender (4,5). were identified between a truncal tumour at first presentaSome promising candidate susceptibility genes are also identition and each of male gender, GSTM1 null and CYP2D6 fied with polymorphism in genes involved in DNA repair EM (P Ͻ0.003, hazard ratios 3.09-3.82). In each of these and detoxification of the products of oxidative stress being cases, all patients with the risk combination demonstrated significant (7-11). Thus, the glutathione S-transferase (GST) further separate tumours within 5 years of first presenta-GSTM1 null genotype in combination with skin type 1 confers tion. Thus, patients with a truncal tumour at first presentaincreased risk of multiple tumours while GSTM1 A/B is tion, especially males and those presenting with more protective (7,8). Allelism at GSTT1 also influences tumour than one lesion have a significantly decreased time to accrual, a finding compatible with the view that these enzymes presentation of further tumours and should receive more are part of the cellular defence against UV-induced oxidative meticulous follow-up. Polymorphism in GSTM1 and stress (9). Polymorphism at the cytochrome P450 CYP2D6 CYP2D6 also influences the rate of new primary tumour and CYP1A1 loci is also associated with tumour numbers and accrual giving insights into the link between ultraviolet accrual (8-9). exposure and multiple tumour development.
A better understanding of the role of genetic factors in the pathogenesis of BCC would be useful as few common cancers offer an opportunity to compare their influence on tumour Introduction numbers, accrual and site. Furthermore, a pilot study from Basal cell carcinoma of skin (BCC*) is the commonest cancer our laboratory indicates an association between BCC and in Caucasians, accounting in 1994, for~35% of all newly susceptibility to haematological malignancies suggesting diagnosed neoplasms in the US (1-3). A remarkable feature shared genetic influences (12) . We now describe, in a large seen in patients who develop BCC is the risk of further, cohort of cases (n ϭ 856), the use of Cox's proportional separate primary tumours (as distinct from recurrence of the hazards model to investigate the influence of genetic and original lesion) (4,5). Importantly, this depends on the number individual characteristics on the time between first tumour of lesions already present: 27% of patients with one tumour presentation and presentation of the next new primary BCC. suffer a further tumour within 5 years compared with 90% of
The influence of a variety of relevant individual characteristics those with 10 or more lesions (5). These data suggest accrual (gender, age, number of tumours at first presentation, skin type, hair colour and eye colour at age 21, smoking status and occupation) is described though particular attention has been *Abbreviations: BCC, basal cell carcinoma; UV, ultraviolet radiation; GST, glutathione-S-transferase; CYP, cytochrome P-450; CI, confidence interval given to tumour site at first presentation to identify the significance of truncal lesions. This parameter has not been 
Patients and methods
Outdoor occupation 11.7% (n ϭ 25) Indoor occupation 88.3% (n ϭ 189) Patients The influence of genotypes and characteristics on time from first to next primary tumour presentation was studied in 856 unrelated Northern European Caucasians with histologically proven BCC. They were recruited between accurate memory in an often elderly population. Where patients presented November 1991 and November 1995 from dermatology clinics in the North with a single tumour, or with more than one tumour but did not suffer a Staffordshire Hospital, Stafford District General Hospital and Royal Cornwall further BCC by November 1995, their times were considered to be censored. Hospitals. Of the total, 566 patients suffered one tumour and 290 patients For these patients the time of appearance of the next tumour obviously exceeds between 2-35 tumours. Of this case group, 435 patients comprised the BCC the study period, or their event-free times must be at least the time to the case group described earlier (7) and data from these patients were included cessation of follow-up. These censored times are incorporated into the in the present study. Patient characteristics and genotype frequencies between calculation of the estimates of the survival probabilities (15) . For all other the original 435 patients and the further 421 recruited between October 1993 multiple BCC patients, the time interval between first presentation of the next and November 1995 were not different. Recurrences of original BCC lesions new primary tumour (not necessarily the second lesion) was used in the were excluded from the total number of primary BCC. No patients with analysis. Cox's proportional hazards regression was used to determine which basal cell naevus syndrome, xeroderma pigmentosum or BCC and another factors, alone and in combination, significantly influenced the time from first malignancy (either internal or cutaneous of a different histological type) were presentation to presentation of a subsequent new tumour (15) . Since number included. Cases comprised over 60% of those in the participating centres and of tumours at presentation, categorized as single versus multiple, was highly were a typical sample of this patient group with patient characteristics significant alone, all subsequent calculations were carried out by correcting comparable to other BCC populations (5). The remaining 40% were inadvertfor this factor (i.e. including it in the regression model together with the ently missed in busy clinics. These patients did not comprise a particular parameter under study). The results are presented as the following summaries; subgroup and were not clinically different to the study group. None of those corrected hazard ratios with 95% confidence intervals and significance levels, approached refused to participate. All patients were examined by a trained and uncorrected median time to next BCC and proportions of patients with dermatologist (JTL, AGS, AHMH, BB) and information on hair (blonde/red further tumours at 3 and 5 years. and brown/black) and eye colour (blue/green and brown) at 21 years of age, skin type (types 1-4), occupation (indoor/outdoor) was obtained (8). A
Results
smoking history was also obtained allowing classification as 'ever' (had previously smoked at least 10 cigarettes/day for at least 5 years or current Patient characteristics smokers) or 'never' smokers were obtained (8). Patients were also questioned Table I shows the characteristics of the cases. The number of regarding ingestion of arsenic-containing tonics or use of drinking water from potentially contaminated wells, though no exposed patients were identified. patients with 1-4, Ͼ4 and Ͼ9 separate primary lesions is The proportion of males was greater than in the 563 agestored at Ϫ50°C until analysis. GSTM1 (null, A, B, A/B) and GSTT1 (null matched controls (47%) from the study centres described by and expressers) genotypes were identified using PCR approaches (9). Two variant CYP2D6 alleles (CYP2D6A, base pair deletion in exon 5; CYP2D6B,
Heagerty et al. (8). Frequencies of GSTM1, GSTT1, CYP2D6
G-A transition at intron 3/exon 4) were also identified using PCR with and CYP1A1 genotypes were not significantly different from diagnostic restriction enzyme digestion (9). These assays are~90% predictive those in these controls (data not shown) (8,9). of phenotype in Europeans (13, 14) . Two variant CYP1A1 alleles (exon 7 IleϪVal and 3Ј flanking region Msp1 mutations) were detected using PCR
Single factors influencing time to presentation of next BCC
with restriction enzyme digestion (9). Comparison of the frequencies of homo- Table II shows the genotypes and characteristics associated and heterozygotic combinations of these two alleles showed they were in with time from first presentation to next new primary BCC. linkage disequilibrium (χ 2 4 ϭ 52.2; P Ͻ 0.0001) (13, 14) .
Data were adjusted for number of tumours at first presentation
Statistical analysis
since, as expected (4,5), the presence of more than one
Methods of survival analysis were used to study factors that influence time tumour at first presentation was significantly associated with from first BCC presentation to presentation of a subsequent new primary tumour. Although in this study, death is not the endpoint, this approach can a decreased time to next tumour (P Ͻ 0.0001, hazard ratio be applied to assess disease 'progression' using other endpoints (15 The results are presented as the following summaries; corrected hazard ratios with 95% confidence intervals and significance levels for the model, and uncorrected median time to next BCC and proportions of patients with further tumours at 3 and 5 years. The hazard ratio is related to odds ratio in casecontrol studies. It can be approximated, assuming no correction for confounding factors, from the ratio of median times to next new BCC presentation in the risk group (e.g. GSTT1 null) divided by the non-risk group (e.g. GSTT1 expressers). a GSTT1 was assessed independent of tumour site (i.e. tumours at all sites are included).
lesion approached significance (Table II) . Male gender also appeared to be associated with a shorter time to presentation of further tumours, though the effect failed to achieve significance (P ϭ 0.0815, hazard ratio 1.38). Skin type, hair colour, eye colour, smoking status and occupation were not significant. GSTT1 null was associated with a significantly reduced time to presentation of next tumour (Table II) whereas GSTM1 null, CYP2D6 EM, CYP1A1 Ile/Ile and CYP1A1 m1m1 were not significant. Table II shows significant two-factor interactions, corrected for number of tumours at first presentation, in which the interaction term was more significant than either of the main effects. Only two-factor interactions were considered. Thus, highly significant two-factor interactions between the presence of the first tumour on the trunk and each of male gender, GSTM1 null genotype and CYP2D6 EM genotype were identified. Data on the interaction between truncal tumour at first presentaion and GSTM1 null genotype are illustrated in Figure 1 . These interactions (truncal tumour ϩ male gender, all of the cases with these combinations demonstrated further tumours within 5 years, whereas only half of the cases without associated with BCC, it is predicted that the prevalence of this these combinations suffered a further lesion during this time tumour will be greater than that for all other cancers combined (Table II) . Indeed, 3 years after first presentation, 78% of the (2). Further, patients with a BCC are often unaware of or, cases with GSTM1 null and a first truncal tumour had suffered ignore the development of further lesions (16, 17) . The ability a further BCC. No significant two-factor interactions between to identify, at first presentation, which patients will develop pairs of GSTM1, GSTT1, CYP2D6 and CYP1A1 genotypes further lesions and at what rate would be useful if it allowed were identified. Other interactions between genotypes and earlier detection of lesions. This is particularly true since patient characteristics, including skin type 1 and male gender smaller tumours are usually more easily removed with better were not significant. cosmetic outcome (18) . We have identified in 856 patients, factors associated with Discussion a rapid time to presentation of next new primary tumour. Although there must be a time interval between appearance We have reported the use of a Cox's proportional hazards model approach to study the influence of GST and CYP of the BCC and presentation to dermatologists, we have used the latter parameter (see statistical anlaysis section). It is our genotypes, patient characteristics and tumour site on the time from first presentation with a BCC to next presentation of a clinical impression that this is a more reliable endpoint than time to tumour appearance determined by the patient, which separate primary BCC. These tumours are a major burden to health-care agencies with incidences in the US as high as 300 is dependent on accurate memory in an often elderly population. While it is possible that the time difference between these two per 100 000 people and reported annual increases of~10% (4). In view of this increasing incidence and the low mortality parameters varies between patients, we detected no significant differences in this interval between the subgroups shown in males are at increased risk of multiple BCC. Outdoor occupation was not a significant factor in our analysis suggesting Table II . As expected, patients with more than one lesion at first presentation demonstrated a decreased median time to cumulative UV-exposure alone is not the explanation. This view is compatible with data showing susceptibility to UVBnext tumour (4,5). We also report, for the first time, that truncal site at presentation in combination with other factors is induced inhibition of contact hypersensitivity appears a better indicator of non-melanoma skin cancer risk than cumulative associated with a reduced median time to next tumour and an increased proportion of patients suffering a further tumour UV exposure (22) . From a statistical viewpoint, the GSTT1 null effect is within 3 and 5 years. Thus, male patients with a truncal tumour at first presentation demonstrate a decreased time to next relatively weak and would require confirmation in subsequent studies. However, since the observations reported here are tumour with all cases suffering a further tumour within 5 years. Since consumption of arsenic is a potential confounding exploratory and not intended to be predictive, correction for multiple analyses is not appropriate. In the case of the factor for truncal tumours, it is noteworthy that the proportion of our cases with truncal tumours was similar to that in other interactive effects, although correction for multiple analyses in exploratory studies is unnecessary, the size of the P value studies of sporadic BCC (19) .
Interactions between genotypes, characteristics and tumour site
Polymorphic variants associated with a decreased time to is such that they are likely to remain significant even after correction. To reduce the risk of spurious association, Chrisnext tumour were also identified; thus GSTT1 null was a significant factor with about two-thirds of these cases suffering tensen (15) recommends that the number of variables tested is 5-10% of the number of cases studied. The number of a further tumour within 5 years compared with only one-third of patients who expressed the gene. GSTM1 and CYP2D6 variables used in this report is considerably less than this. The biochemical processes that determine rate of appearance genotypes alone did not influence subsequent tumour presentation time, though significant interactions with truncal site were of further tumours in BCC are unclear. Our data indicate patients with a truncal tumour at presentation, especially males identified. Thus, cases with a truncal tumour at first presentation and GSTM1 null, demonstrated a markedly decreased time to and those presenting with more than one lesion should receive meticulous and more frequent follow-up to expedite early next lesion such that all patients with this combination suffered a further tumour within 5 years. We speculate the influence of diagnosis. Our data show that inter-individual differences in the efficiency of detoxification reactions also determine GSTM1 and GSTT1 results from their ability to metabolize the products of UV-induced oxidative stress in the skin, a view susceptibility. Thus, the highly significant influence of GSTM1 null or CYP2D6 EM on time to next tumour presentation supported by the finding that GSTM1 null is associated with photosensitive systemic lupus erythematosus via increased suggests a possible use of genetic markers in a followup strategy. production of anti-Ro (but not anti-La) antibodies (20) . However, unlike GSTM1 null, no interaction between GSTT1 null and tumour site was found, a finding that complements data
